United Therapeutics Option Alert: May 16 $310 Calls at the Bid: 400 vs 1 OI; Earnings 4/30 Before Open [est] 

United Therapeutics Option Alert: May 16 $310 Calls at the Bid: 400 @ $13.2 vs 1 OI; Earnings 4/30 Before Open [est] Ref=$306.32

United Therapeutics Option Alert: May 16 $310 Calls at the Bid: 500 vs 1 OI; Earnings 4/30 Before Open [est] 

United Therapeutics Option Alert: May 16 $310 Calls at the Bid: 500 @ $13.8 vs 1 OI; Earnings 4/30 Before Open [est] Ref=$306.49

United Therapeutics (NASDAQ:UTHR) Bolsa

UNITED THERAPEUTICS CORP

United Therapeutics

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

United Therapeutics Corporation - Common Stock

United Therapeutics Corp

In the last three months, 7 analysts have published ratings on United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $358.71, a high estimate of $425.00, and a low estimate of $314.00. A decline of 1.81% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1748872832_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of United Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$405.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$425.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$348.00</td>
<td>$346.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$314.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$355.00</td>
<td>$357.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$314.00</td>
<td>$314.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to United Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of United Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of United Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into United Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UTHR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on United Therapeutics analyst ratings.</a>
<h2>Get to Know United Therapeutics Better</h2>
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
<h3>United Therapeutics's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: United Therapeutics displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 17.22%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: United Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 40.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): United Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.86% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): United Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.27% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: United Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.03.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

UTHR

Forecasting The Future: 7 Analyst Projections For United Therapeutics

Cantor Fitzgerald analyst Olivia Brayer initiates coverage on United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Overweight rating and announces Price Target of $405.

News

Price Target

Initiation

Cantor Fitzgerald Initiates Coverage On United Therapeutics with Overweight Rating, Announces Price Target of $405

On Friday, the U.S. Food and Drug Administration (FDA) approved Liquidia Corporation&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) Yutrepia (treprostinil) inhalation powder, a prostacyclin analog for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">improve exercise ability</a>.
In August 2024, the FDA issued tentative approval of Yutrepia for the PAH and PH-ILD indications.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40752393/fda-battles-backlog-of-drug-factory-inspections-since-covid-19" rel="noreferrer noopener">FDA Battles Backlog of Drug Factory Inspections Since COVID-19</a>
Yutrepia is the first and only prostacyclin dry-powder formulation enabled by Liquidia&#8217;s proprietary PRINT technology, which yields uniform, free-flowing particles designed to enhance deep-lung delivery via an easy-to-use, low-effort device requiring <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45593900/u-s-fda-approves-liquidias-yutrepia-treprostinil-inhalation-powder-for-patients-with-pulmonary-art" rel="noreferrer noopener">less inspiratory effort</a>.
The approval of Yutrepia is based on findings from the Phase 3 INSPIRE trial, which evaluated patients who were naïve to treprostinil and those transitioning to Yutrepia from nebulized treprostinil.
Yutrepia was shown to be safe and well-tolerated regardless of a patient&#8217;s previous exposure to treprostinil.
As previously disclosed, United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) filed a complaint on May 9, in the U.S. District Court for the Middle District of North Carolina against Liquidia, alleging infringement of U.S. Patent No. 11,357,782. The complaint seeks to enjoin Liquidia from commercializing Yutrepia <a href="https://www.benzinga.com/pressreleases/25/05/g45593900/u-s-fda-approves-liquidias-yutrepia-treprostinil-inhalation-powder-for-patients-with-pulmonary-art" target="_blank" rel="noreferrer noopener">to treat PAH and PH-ILD</a>.
United Therapeutics has filed a motion for a temporary restraining order and preliminary injunction to block Liquidia from commercially launching Yutrepia. An oral argument on the motion was held on May 20, 2025. The motion remains pending with the Court.
In March, Liquidia&nbsp;entered into a sixth amendment to its agreement with HealthCare Royalty to provide up to an additional&nbsp;$100 million of financing <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45279833/liquidia-corporation-reports-first-quarter-2025-financial-results-and-provides-corporate-update" rel="noreferrer noopener">in three tranches</a>.&nbsp;
The company&nbsp;intends to use the proceeds to fund ongoing commercial development of Yutrepia, continued development of Yutrepia in other clinical trials, including but not limited to trials for pediatric patients, and trials further evaluating the use of Yutrepia in&nbsp;PAH and PH-ILD patients, clinical development of L606, a sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and for general corporate purposes.
Price Action: LQDA stock is down 3.3% at $14.84 on the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45614776/why-is-prothena-stock-trading-lower-on-tuesday" target="_blank" rel="noreferrer noopener">Why Is Prothena Stock Trading Lower On Tuesday?</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

General

LQDA

Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge

<ul>
<li>Additionally, the complaint seeks to enjoin Liquidia from commercializing YUTREPIA (treprostinil) inhalation powder if approved by the U.S. Food and Drug Administration (FDA) to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).</li>
<li>The ‘782 patent, which issued on June 14, 2022, arises out of the same patent family as U.S. Patent No. 10,716,793 (the ‘793 patent) and claims the same general method of administering inhaled treprostinil to pulmonary hypertension patients. As disclosed in July 2022, the ‘793 patent was held to be invalid in a proceeding before the Patent Trial and Appeal Board (PTAB). The PTAB's decision was affirmed by the&nbsp;U.S. Court of Appeals for the Federal Circuit&nbsp;in&nbsp;December 2023. The United States Supreme Court&nbsp;rejected UTHR's petition for a writ of certiorari, thereby upholding PTAB's decision which found that all claims of the ‘793 patent are unpatentable due to prior art as final and not subject to further appeal.</li>
<li>UTHR is currently not seeking any injunction against the FDA to prevent final approval of the New Drug Application (NDA) for YUTREPIA. As previously announced, the FDA set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025.</li>
</ul>

Legal

United Therapeutics Corporation Filed A Complaint On May 9, 2025, In The U.S. District Court For The Middle District Of North Carolina Against Liquidia Alleging Infringement Of U.S. Patent No. 11,357,782.

HC Wainwright &amp; Co. analyst Andrew Fein reiterates United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Buy and maintains $425 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $425 Price Target

JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Overweight and lowers the price target from $355 to $350.

JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $350

Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Equal-Weight and raises the price target from $346 to $348.

Morgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $348

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) reported quarterly earnings of $6.63 per share which beat the analyst consensus estimate of $6.52 by 1.69 percent. This is a 7.46 percent increase over earnings of $6.17 per share from the same period last year. The company reported quarterly sales of $794.40 million which beat the analyst consensus estimate of $729.83 million by 8.85 percent. This is a 17.22 percent increase over sales of $677.70 million the same period last year.

Earnings

Earnings Beats

United Therapeutics Q1 EPS $6.63 Beats $6.52 Estimate, Sales $794.40M Beat $729.83M Estimate

AEIS

ALGN

ALKT

AMCR

ANSS

ARAY

ATNI

AWRE

BLCO

BLFY

BLKB

BXMT

CACC

CAKE

CDNA

CFLT

CGNX

CHEF

CHRW

CLMB

CMPR

CNMD

CNXN

COCO

COKE

CPSH

CSLR

CSTM

CTOS

CTSH

CVEO

CWAN

CWEN

DFIN

EBAY

ENVX

EQIX

EQNR

ETSY

EXTR

FCPT

FFWM

FINW

FMBH

FORM

FTAI

GEHC

GKOS

GNRC

GRBK

GRMN

GTES

Earnings Scheduled For April 30, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan analyst Eric Joseph initiated coverage on OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Neutral rating. OPKO Health shares closed at $1.46 on Thursday. <a href="https://www.benzinga.com/quote/OPK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Asiya Merchant initiated coverage on Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) with a Neutral rating and announced a price target of $39. Super Micro Computer shares closed at $35.81 on Thursday. <a href="https://www.benzinga.com/quote/SMCI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Rich Kwas initiated coverage on Sensata Technologies Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) with an Equal-Weight rating and announced a price target of $20. Sensata Technologies shares closed at $21.64 on Thursday. <a href="https://www.benzinga.com/quote/ST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li> Needham analyst Ryan Koontz initiated coverage on Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) with a Buy rating and announced a price target of $28. Rocket Lab USA shares closed at $21.88 on Thursday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying OPK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="614" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25083217/image-176-1024x614.png" alt="" class="wp-image-888690" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25083217/image-176-1024x614.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25083217/image-176-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25083217/image-176-768x461.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25083217/image-176.png 1072w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45001899/alphabet-intel-and-3-stocks-to-watch-heading-into-friday">Alphabet, Intel And 3 Stocks To Watch Heading Into Friday</a> </li>
</ul>
Photo via Shutterstock

Markets

Trading Ideas

RKLB

SMCI

This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Canaccord Genuity analyst Joseph Vafi downgraded the rating for ASGN Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) from Buy to Hold and lowered the price target from $115 to $55. ASGN shares closed at $51.76 on Thursday. <a href="https://www.benzinga.com/quote/ASGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Alexei Gogolev downgraded SS&amp;C Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>) from Overweight to Neutral and lowered the price target from $90 to $86. SS&amp;C Technologies shares closed at $77.43 on Thursday. <a href="https://www.benzinga.com/quote/SSNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie analyst Linda Huang downgraded the rating for TAL Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) from Outperform to Neutral and cut the price target from $14.5 to $10.9. TAL Education shares closed at $8.93 on Thursday. <a href="https://www.benzinga.com/quote/TAL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Tiago Fauth downgraded United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) from Overweight to Equal-Weight and slashed the price target from $395 to $314. United Therapeutics shares closed at $296.42 on Thursday. <a href="https://www.benzinga.com/quote/UTHR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying UTHR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="632" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072624/image-173-1024x632.png" alt="" class="wp-image-888521" style="width:611px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072624/image-173-1024x632.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072624/image-173-300x185.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072624/image-173-768x474.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072624/image-173.png 1065w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45001899/alphabet-intel-and-3-stocks-to-watch-heading-into-friday">Alphabet, Intel And 3 Stocks To Watch Heading Into Friday</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

ASGN

SSNC

This United Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday

Across the recent three months, 4 analysts have shared their insights on United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $352.0, a high estimate of $425.00, and a low estimate of $314.00. This current average represents a 5.57% decrease from the previous average price target of $372.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1745582487_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive United Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Tiago Fauth &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $314.00&#x7C;$395.00 &#x7C; 
&#x7C;Jessica Fye &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $355.00&#x7C;$357.00 &#x7C; 
&#x7C;Greg Harrison &#x7C;B of A Securities &#x7C;Maintains &#x7C;Neutral &#x7C; $314.00&#x7C;$314.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $425.00&#x7C;$425.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to United Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of United Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of United Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into United Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/UTHR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on United Therapeutics analyst ratings.</a>
<h2>Delving into United Therapeutics's Background</h2>
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
<h3>United Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining United Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 19.72% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: United Therapeutics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 40.94%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): United Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of 4.8%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): United Therapeutics's ROA excels beyond industry benchmarks, reaching 4.16%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.05.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying United Therapeutics: Insights From 4 Analyst Reviews

Wells Fargo analyst Tiago Fauth downgrades United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) from Overweight to Equal-Weight and lowers the price target from $395 to $314.

Wells Fargo Downgrades United Therapeutics to Equal-Weight, Lowers Price Target to $314

JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Overweight and lowers the price target from $357 to $355.

JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $355

B of A Securities analyst Greg Harrison upgrades United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) from Underperform to Neutral and maintains the price target from $314 to $314.

Upgrades

B of A Securities Upgrades United Therapeutics to Neutral, Maintains Price Target to $314

United Therapeutics Announces Series Of Presentations And Sponsored Events At ATS 2025, Highlighting Pulmonary Hypertension And Fibrosis Studies

United Therapeutics Corporation Says It Will Feature Clinical Data Across Its Commercial And Development Portfolio At International Society For Heart And Lung Transplantation 45th Annual Meeting And Scientific Sessions

WIIM

United Therapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results.

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) reported quarterly earnings of $6.19 per share which missed the analyst consensus estimate of $6.27 by 1.28 percent. This is a 41.97 percent increase over earnings of $4.36 per share from the same period last year. The company reported quarterly sales of $735.90 million which beat the analyst consensus estimate of $734.74 million by 0.16 percent. This is a 19.72 percent increase over sales of $614.70 million the same period last year.

United Therapeutics Q4 2024 GAAP EPS $6.19 Misses $6.27 Estimate, Sales $735.90M Beat $734.74M Estimate

Press Releases

United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025

United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025

United Therapeutics Named to '100 Best Companies to Work For' in 2025 by Fortune Media and Great Place to Work

United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions

United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
03:58 PMApr 01, 2025	CALL	$310.00	May 16, 2025	-22	1150	400	115000	1	TRADE	BEARISH
02:47 PMApr 01, 2025	CALL	$310.00	May 16, 2025	-22	750	500	75000	1	TRADE	BEARISH

Comments

United Therapeutics

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL